Virus-like particles for the prevention of human papillomavirus-associated malignancies

Joshua W. Wang, Richard S Roden

Research output: Contribution to journalArticle

Abstract

As compared with peptide- or protein-based vaccines, naked DNA vectors and even traditional attenuated or inactivated virus vaccines, virus-like particles (VLPs) are an attractive vaccine platform, as they offer a combination of safety, ease of production and both high-density B-cell epitope display and intracellular presentation of T-cell epitopes that induce potent humoral and cellular immune responses, respectively. Indeed, HPV vaccines based on VLP production by recombinant expression of major capsid antigen L1 in yeast (Gardasil®, Merck & Co., NJ, USA) or insect cells (Cervarix®, GlaxoSmithKline, London, UK) have been licensed for the prevention of cervical and anogenital infection and disease associated with the genotypes targeted by each vaccine. However, these HPV vaccines have not been demonstrated as effective to treat existing infections, and efforts to develop a therapeutic HPV vaccine continue. Furthermore, current HPV L1-VLP vaccines provide type-restricted protection, requiring highly multivalent formulations to broaden coverage to the dozen or more oncogenic HPV genotypes. This raises the complexity and cost of vaccine production. The lack of access to screening and high disease burden in developing countries has spurred efforts to develop second-generation HPV vaccines that are more affordable, induce wider protective coverage and offer therapeutic coverage against HPV-associated malignancies. Given the previous success with L1-VLP-based vaccines against HPV, VLPs have been also adopted as platforms for many second-generation HPV and non-HPV vaccine candidates with both prophylactic and therapeutic intent. In this article, the authors examine the progress and challenges of these efforts, with a focus on how they inform VLP vaccine design.

Original languageEnglish (US)
Pages (from-to)129-141
Number of pages13
JournalExpert Review of Vaccines
Volume12
Issue number2
DOIs
StatePublished - Feb 2013

Fingerprint

Virus-Like Particle Vaccines
Papillomavirus Vaccines
Virion
Vaccines
Neoplasms
Genotype
Leukocyte L1 Antigen Complex
B-Lymphocyte Epitopes
Inactivated Vaccines
DNA Vaccines
T-Lymphocyte Epitopes
Capsid
Humoral Immunity
Infection
Cellular Immunity
Developing Countries
Insects
Therapeutics
Yeasts
Viruses

Keywords

  • cervical cancer
  • HPV
  • HPV prophylactic vaccines
  • L1
  • L2
  • minor capsid protein
  • virus-like particles

ASJC Scopus subject areas

  • Immunology
  • Drug Discovery
  • Pharmacology
  • Molecular Medicine

Cite this

Virus-like particles for the prevention of human papillomavirus-associated malignancies. / Wang, Joshua W.; Roden, Richard S.

In: Expert Review of Vaccines, Vol. 12, No. 2, 02.2013, p. 129-141.

Research output: Contribution to journalArticle

@article{e86944575ca641dbabaa96187eafda69,
title = "Virus-like particles for the prevention of human papillomavirus-associated malignancies",
abstract = "As compared with peptide- or protein-based vaccines, naked DNA vectors and even traditional attenuated or inactivated virus vaccines, virus-like particles (VLPs) are an attractive vaccine platform, as they offer a combination of safety, ease of production and both high-density B-cell epitope display and intracellular presentation of T-cell epitopes that induce potent humoral and cellular immune responses, respectively. Indeed, HPV vaccines based on VLP production by recombinant expression of major capsid antigen L1 in yeast (Gardasil{\circledR}, Merck & Co., NJ, USA) or insect cells (Cervarix{\circledR}, GlaxoSmithKline, London, UK) have been licensed for the prevention of cervical and anogenital infection and disease associated with the genotypes targeted by each vaccine. However, these HPV vaccines have not been demonstrated as effective to treat existing infections, and efforts to develop a therapeutic HPV vaccine continue. Furthermore, current HPV L1-VLP vaccines provide type-restricted protection, requiring highly multivalent formulations to broaden coverage to the dozen or more oncogenic HPV genotypes. This raises the complexity and cost of vaccine production. The lack of access to screening and high disease burden in developing countries has spurred efforts to develop second-generation HPV vaccines that are more affordable, induce wider protective coverage and offer therapeutic coverage against HPV-associated malignancies. Given the previous success with L1-VLP-based vaccines against HPV, VLPs have been also adopted as platforms for many second-generation HPV and non-HPV vaccine candidates with both prophylactic and therapeutic intent. In this article, the authors examine the progress and challenges of these efforts, with a focus on how they inform VLP vaccine design.",
keywords = "cervical cancer, HPV, HPV prophylactic vaccines, L1, L2, minor capsid protein, virus-like particles",
author = "Wang, {Joshua W.} and Roden, {Richard S}",
year = "2013",
month = "2",
doi = "10.1586/erv.12.151",
language = "English (US)",
volume = "12",
pages = "129--141",
journal = "Expert Review of Vaccines",
issn = "1476-0584",
publisher = "Expert Reviews Ltd.",
number = "2",

}

TY - JOUR

T1 - Virus-like particles for the prevention of human papillomavirus-associated malignancies

AU - Wang, Joshua W.

AU - Roden, Richard S

PY - 2013/2

Y1 - 2013/2

N2 - As compared with peptide- or protein-based vaccines, naked DNA vectors and even traditional attenuated or inactivated virus vaccines, virus-like particles (VLPs) are an attractive vaccine platform, as they offer a combination of safety, ease of production and both high-density B-cell epitope display and intracellular presentation of T-cell epitopes that induce potent humoral and cellular immune responses, respectively. Indeed, HPV vaccines based on VLP production by recombinant expression of major capsid antigen L1 in yeast (Gardasil®, Merck & Co., NJ, USA) or insect cells (Cervarix®, GlaxoSmithKline, London, UK) have been licensed for the prevention of cervical and anogenital infection and disease associated with the genotypes targeted by each vaccine. However, these HPV vaccines have not been demonstrated as effective to treat existing infections, and efforts to develop a therapeutic HPV vaccine continue. Furthermore, current HPV L1-VLP vaccines provide type-restricted protection, requiring highly multivalent formulations to broaden coverage to the dozen or more oncogenic HPV genotypes. This raises the complexity and cost of vaccine production. The lack of access to screening and high disease burden in developing countries has spurred efforts to develop second-generation HPV vaccines that are more affordable, induce wider protective coverage and offer therapeutic coverage against HPV-associated malignancies. Given the previous success with L1-VLP-based vaccines against HPV, VLPs have been also adopted as platforms for many second-generation HPV and non-HPV vaccine candidates with both prophylactic and therapeutic intent. In this article, the authors examine the progress and challenges of these efforts, with a focus on how they inform VLP vaccine design.

AB - As compared with peptide- or protein-based vaccines, naked DNA vectors and even traditional attenuated or inactivated virus vaccines, virus-like particles (VLPs) are an attractive vaccine platform, as they offer a combination of safety, ease of production and both high-density B-cell epitope display and intracellular presentation of T-cell epitopes that induce potent humoral and cellular immune responses, respectively. Indeed, HPV vaccines based on VLP production by recombinant expression of major capsid antigen L1 in yeast (Gardasil®, Merck & Co., NJ, USA) or insect cells (Cervarix®, GlaxoSmithKline, London, UK) have been licensed for the prevention of cervical and anogenital infection and disease associated with the genotypes targeted by each vaccine. However, these HPV vaccines have not been demonstrated as effective to treat existing infections, and efforts to develop a therapeutic HPV vaccine continue. Furthermore, current HPV L1-VLP vaccines provide type-restricted protection, requiring highly multivalent formulations to broaden coverage to the dozen or more oncogenic HPV genotypes. This raises the complexity and cost of vaccine production. The lack of access to screening and high disease burden in developing countries has spurred efforts to develop second-generation HPV vaccines that are more affordable, induce wider protective coverage and offer therapeutic coverage against HPV-associated malignancies. Given the previous success with L1-VLP-based vaccines against HPV, VLPs have been also adopted as platforms for many second-generation HPV and non-HPV vaccine candidates with both prophylactic and therapeutic intent. In this article, the authors examine the progress and challenges of these efforts, with a focus on how they inform VLP vaccine design.

KW - cervical cancer

KW - HPV

KW - HPV prophylactic vaccines

KW - L1

KW - L2

KW - minor capsid protein

KW - virus-like particles

UR - http://www.scopus.com/inward/record.url?scp=84874096730&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874096730&partnerID=8YFLogxK

U2 - 10.1586/erv.12.151

DO - 10.1586/erv.12.151

M3 - Article

C2 - 23414405

AN - SCOPUS:84874096730

VL - 12

SP - 129

EP - 141

JO - Expert Review of Vaccines

JF - Expert Review of Vaccines

SN - 1476-0584

IS - 2

ER -